Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Moretsky Cassidy Vision Correction was an Arizona ophthalmology and refractive-surgery practice focused on LASIK, cataract surgery, and related vision-correction services. The practice marketed bladeless/iLASIK procedures and cataract care delivered by ophthalmologists associated with the Moretsky and Cassidy names, with locations in the Phoenix metropolitan area including Mesa and Phoenix/Glendale-area sites. It operated as a commercial healthcare services business rather than a drug-development biotech or pharma company, so it did not have a therapeutic pipeline in the traditional biopharma sense. In March 2026, the organization announced that effective April 1, 2026, its services would transition to Barnet Dulaney Perkins Eye Center, indicating that the Moretsky Cassidy brand is no longer operating as a standalone active entity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Moretsky Cassidy Vision Correction.